{
  "ANSWER_QUALITY": {
    "question_one": {
      "text": "What are the Make Early Diagnosis to Prevent Early Death criteria for determining familial hypercholesterolemia?",
      "index": 0,
      "answers": [
        {
          "text": "The Make Early Diagnosis to Prevent Early Death (MEDPED) criteria for determining familial hypercholesterolemia (FH) are based on age-specific total cholesterol or LDL-C thresholds (untreated) and have a high correlation to genetically proven FH. The specific thresholds vary by age and sex.",
          "system": "experiment_1e",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        },
        {
          "text": "The Make Early Diagnosis to Prevent Early Death (MEDPED) criteria for determining familial hypercholesterolemia (FH) are based on age-specific total cholesterol or LDL-C thresholds (untreated) and have a high correlation to genetically proven FH . Patients presumed to have FH are defined by LDL-C levels that meet MEDPED criteria for FH who are not on lipid-lowering therapy (LLT) or LDL-C levels above a threshold defined by adjusting MEDPED criteria by factoring a 30% reduction in LDL-C for patients adherent to LLT meeting American Heart Association guidelines for moderate- or high-intensity statins .",
          "system": "experiment_5a",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        },
        {
          "text": "Sorry, there is no relevant text in the given portion of the document to answer this question.",
          "system": "experiment_4a",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        }
      ]
    },
    "question_two": {
      "text": "What are the rejection rates for PCSK9 inhibitor prescriptions in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease?",
      "index": 0,
      "answers": [
        {
          "text": "The rejection rates for PCSK9 inhibitor prescriptions in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease are high. For example, 63.3% of prescriptions for PCSK9 inhibitors were rejected in presumptive FH patients who had an LDL-C value >190 mg/dL despite evidence of statin-based LLT. Similarly, 57.5% of PCSK9 inhibitor prescriptions were rejected in ASCVD patients who had an LDL-C value >100 mg/dL despite evidence of high-intensity or moderate-intensity statin.",
          "system": "experiment_1e",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        },
        {
          "text": "High-risk patients with presumptive familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) have high rates of rejection for PCSK9 inhibitor (PCSK9i) prescriptions, with 63.3% of prescriptions for PCSK9 inhibitors being rejected in FH patients with an LDL-C value >190 mg/dL despite evidence of statin-based LLT, and 57.5% of PCSK9 inhibitor prescriptions being rejected in patients with established ASCVD who had an LDL-C value >100 mg/dL despite evidence of being treated with appropriate LLT  . Sensitivity analyses showed similar rejection rates for PCSK9 inhibitors in those with LDL-C >130 or >160 mg/dL (57.7% and 57.8%, respectively) . Of PCSK9 inhibitor prescriptions that were ultimately approved for either the presumptive FH patients or those with ASCVD, 34% were approved within 30 days, whereas approval took >2 months for 40% of prescriptions . The FOCUS study (FH Optimal Care of the US) was designed by The FH Foundation to assess current treatment patterns of FH patients, and allowed us to assess rejection rates of PCSK9 inhibitors in those with FH or ASCVD .",
          "system": "experiment_5a",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        },
        {
          "text": "The rejection rates for PCSK9 inhibitor prescriptions in patients with familial hypercholesterolemia who had an LDL-C value >190 mg/dL despite evidence of statin-based LLT was 63.3%. For patients with presumptive FH who had an LDL-C value >190 mg/dL despite evidence of being treated with appropriate LLT, 69.7% of PCSK9 inhibitor prescriptions were rejected. For patients with established ASCVD who had an LDL-C value >100 mg/dL despite evidence of being treated with appropriate LLT, 57.5% of PCSK9 inhibitor prescriptions were rejected.",
          "system": "experiment_4a",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        }
      ]
    },
    "question_three": {
      "text": "What are the potential challenges in operationalizing the results of the FOURIER trial?",
      "index": 0,
      "answers": [
        {
          "text": "The FOCUS data indicate that high-risk patients, including those with presumptive FH or ASCVD, have high rates of rejection for PCSK9i prescriptions even when there is sufficient evidence that they have inadequately controlled LDL-C despite concurrent appropriate statin-based LLT. This suggests that access to nonstatin LLTs has been a challenge for FH patients, although this has not been systematically evaluated. These data highlight potential challenges in operationalizing the results of the FOURIER trial.",
          "system": "experiment_1e",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        },
        {
          "text": "The potential challenges in operationalizing the results of the FOURIER trial include high rates of rejection for PCSK9 inhibitor prescriptions, even in high-risk patients with inadequately controlled LDL-C despite concurrent appropriate statin-based lipid-lowering therapy   . The rejection rates for PCSK9 inhibitors were higher than those for ezetimibe  . However, of the PCSK9 inhibitor prescriptions that were ultimately approved, 34% were approved within 30 days, whereas approval took over two months for 40% of prescriptions . These findings were based on the FOCUS study (FH Optimal Care of the US) designed by The FH Foundation to assess current treatment patterns of FH patients .",
          "system": "experiment_5a",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        },
        {
          "text": "The first sentence states that the article does not provide information on the potential challenges in operationalizing the results of the FOURIER trial. The second sentence contradicts this by saying that the data highlight potential challenges, but it does not specify what those challenges are. Therefore, it is unclear what the potential challenges are in operationalizing the results of the FOURIER trial.",
          "system": "experiment_4a",
          "overall_rating": 1,
          "Does this answer provide enough information for the question?": "",
          "Does this answer provide inaccurate information?": "",
          "Does this answer provide information not found in the document?": "",
          "Does this answer completely answer the whole question?": "",
          "Is it easy to read this answer?": "",
          "Is this answer relevant to the question?": "",
          "Do you feel the answer is wordy?": "",
          "Do you believe or trust this answer?": "",
          "Do you need more details?": "",
          "Are there any new ideas or concepts in this answer that make you somewhat surprised?": "",
          "Is this answer useful or helpful to address the question?": "",
          "Do you think this answer has been written by an expert?": ""
        }
      ]
    }
  },
  "GENERATED_QUESTIONS": {
    "question_one": {
      "text": "What are the Make Early Diagnosis to Prevent Early Death criteria for determining familial hypercholesterolemia?",
      "highlights": []
    },
    "question_two": {
      "text": "What are the rejection rates for PCSK9 inhibitor prescriptions in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease?",
      "highlights": []
    },
    "question_three": {
      "text": "What are the potential challenges in operationalizing the results of the FOURIER trial?",
      "highlights": []
    }
  }
}
